共查询到16条相似文献,搜索用时 263 毫秒
1.
2.
以碘作催化剂, 无水苯为溶剂, 六乙基亚磷酰三胺依次与羟乙基替加氟、1-芳硒基甘油及硫反应, 得中间体硒代环甘油磷脂替加氟缀合物2a~2f. 以无水N,N-二甲基甲酰胺(DMF)作溶剂, 室温下, 叠氮化钠中对2a~2f进行亲核开环, 得到O-(1-芳硒基-3-叠氮基)异丙基-O-2-(N3-替加氟)乙基硫代磷酯. 体外活性测试结果表明, 目标化合物3a~3f 对膀胱癌细胞PGA1抑制作用比替加氟高, 对胃癌细胞BGC-823的抑制作用与替加氟相当. 相似文献
3.
4.
5.
N3-羟烷基替加氟制备方法改良及其环甘油磷脂缀合物的合成与抗肿瘤活性 总被引:2,自引:0,他引:2
在药物-载体复合型前药的研究中,磷脂-药物缀合物(如脂核苷酸)特别引人注目,它以磷脂作为载体,与核苷等药物分子以共价连接形成的一类新型脂核苷酸前药[1~3]. 相似文献
6.
合成了11个新的硫羰磷酸酯及其11个异构化产物硫羟磷酸酯,其结构经1HNMR、元素分析证实。研究了温度、溶剂对异构化反应的影响,并对反应机理进行了讨论。 相似文献
7.
2,4-二氟苯甲酸或2-氟苯甲酸与二氯亚砜经酰氯化反应,再与邻氨基苯甲酸反应后在醋酸酐中闭环,最后与取代苯并噻唑胺反应合成了9个新型的N-[2-(取代苯并噻唑-2-氨基甲酰基)苯基]取代氟基苯甲酰胺(6a~6i),其结构经1H NMR,13C NMR,IR和元素分析表征。采用MTT法对6a~6i进行抑制PC3癌细胞体外活性测试,结果表明6a~6i具有不同程度的抑制PC3癌细胞活性,其中10μmol.L-16b对PC3的抑制率为69.9%。 相似文献
8.
9.
10.
以白杨素(1)为起始原料,与溴代羧酸乙酯经取代反应制得中间体7-O-乙氧羰基烷基白杨素(3a~3d);3a~3d经水解反应合成了7-O-羧烷基化的白杨素衍生物(4a~4d),其中4b~4d为新化合物,其结构经1H NMR,13C NMR,IR和ESI-MS表征。初步的体外抗癌活性实验结果表明,3和4对人肝癌细胞Hep G2和人胃癌细胞MGC-803具有一定的抗癌活性,且大多数化合物的抗癌活性比母体化合物1强,其中6-(5-羟基-2-苯基-4H-苯并吡喃酮-7-氧)己酸(4d,IC504.04μmol·L-1)对MGC-803细胞的活性抑制作用强于阳性药物DDP(IC504.40μmol·L-1)。 相似文献
11.
1mrnODUCnONBenzisoselenazolones(BISAs)representanewclassofanti--inflammatoryagentasanexampleofseleno-organiccompoundsintherapyofoxidativestresslinkedpathologicalconditions(li.Amongthem,ebselen(2--phenyl--1,2--benzisoselenazol-3(2H)--one,PZ51)hasbeenacceptedasthebestmimicOfGSH-Px(Zi.InadditiontoitsGSH--Px-likeactivityt'nvdro,ithasbeenreportedthatebselencaninhibit5liPOxygenaseandNOsynthase"',isomeriseLTB.toabiologicallyinactiveisomer[41andinhibitthemigrationofPMNLandSPLTintotheinf… 相似文献
12.
根据活性基团拼合原理, 用2-氯硒基苯甲酰氯和2-氨基-5取代-1,3,4-噻二唑缩合合成了10个新的2-(2-取代- 1,3,4-噻二唑-5-基)-苯并异硒唑-3(2H)-酮衍生物(6), 并通过IR, 1H NMR, ESI-MS和元素分析对其结构进行了确认, 采用CCK-8法测试了化合物抑制肿瘤细胞增殖活性. 结果表明, 化合物6h对人体肺癌细胞A-549, 化合物6a, 6b, 6d, 6e, 6f, 6g, 6h, 6j对人体乳腺癌细胞MCF-7, 化合物6a, 6b, 6d, 6e, 6f, 6g对人体肝癌细胞SSMC-7721抑制活性均强于阳性对照药依布硒啉, 且表现出一定的选择性, 具有进一步研究的潜在价值. 相似文献
13.
ZHU Wen-Wen SONG Yun-Long ZHENG Can-Hui LV Jia-Guo CHEN Jun HUANG Jing-Jing ZHOU You-Jun ZHU Ju 《结构化学》2011,30(5):717-723
A novel class of 3,4-dihydroisoquinolines (7a~e) was designed, synthesized and characterized by IR, NMR and ESI-MS. The crystal structure of compound 7a (6,7,8-trime- thoxy-1-(4-methoxy-3-nitrophenyl)-4-(pyridin-4-methyl)-3,4-dihydroisoquinoline, C25H25N3O6, Mr=463.48) was determined by X-ray diffraction analysis. The crystal belongs to the monoclinic system, space group P21/n with a=12.074(5), b=12.896(6), c=15.450(7), β=105.846(5)°, V=2314.4(17) 3, Z=4, Dc=1.330 Mg/m3, μ(MoKα)=0.096 mm-1, F(000)=976, S=0.991, the final R=0.0467 and wR=0.1231 for 4545 unique reflections (Rint=0.0656) with 3117 observed ones. The bioassay showed that compounds 7a~e exhibit moderate antitumor activities in vitro. 相似文献
14.
Han Luo Yong-Feng Lv Hong Zhang Jiang-Miao Hu Hong-Mei Li Shou-Jin Liu 《Molecules (Basel, Switzerland)》2021,26(11)
A new series of mollugin-1,2,3-triazole derivatives were synthesized using a copper(I)-catalyzed Huisgen 1,3-dipolar cycloaddition reaction of corresponding O-propargylated mollugin with aryl azides. All the compounds were evaluated for their cytotoxicity on five human cancer cell lines (HL-60, A549, SMMC-7721, SW480, and MCF-7) using MTS assays. Among the synthesized series, most of them showed cytotoxicity and most of all, compounds 14 and 17 exhibited significant cytotoxicity of all five cancer cell lines. 相似文献
15.
报道一种新型1,2,4-噁二唑衍生物,N-[2,6-二氯-4-(1,2,4-噁二唑-3-基)苯基]-2-甲氧基烟酰胺(C15H10Cl2N4O3)的合成,其结构通过1H NMR、13C NMR、HRMS以及X-射线单晶衍射进行表征。该晶体结构属于三斜晶系, P 1(—) 空间群,晶胞参数 a = 7.1291 (9), b = 8.4352 (10), c = 14.0021 (18) ?, α = 73.834 (3), β = 77.407 (3), γ = 70.019 (3)°, Mr = 366.18, V = 752.97 (16) ?3, Z = 2, Dc = 1.611 g/cm3, μ(MoKα) = 0.454 mm-1, F(000) = 372.0 , 晶体尺寸为 0.36 × 0.2 × 0.1 mm,Rint = 0.023。初步活性研究发现,该化合物对LoVo, A549, SK-BR-3, HeLa这四种肿瘤细胞株具有明显的抑制作用,尤其是对HeLa细胞的抑制活性与阳性药物5-氟尿嘧啶 (5-FU)相当。 相似文献
16.
The title compound, N-(2-(1H-indol-3-yl)ethyl)-2-nitroaniline(C16H15N3O2, Mr = 281.31), has been synthesized by the multicomponent reaction of milder Ullmann, and its structure was characterized by 1H NMR, 13 C NMR, IR, H RMS(ESI) and single-crystal X-ray diffraction. It crystallizes in monoclinic, space group I2/c with a = 15.0212(10), b = 9.4911(6), c = 20.3075(13) A, β = 100.776(7)o, V = 2844.1(3)A3, Z = 8, Dc = 1.314 g/cm3, F(000) = 1184.0, μ = 0.089 mm-1, the final R = 0.0574 and w R = 0.1688 for 1701 observed reflections(I 2σ(I)). X-ray analysis indicates three major N(2)–H(2)···O(2), C(13)–H(13)···O(2), N(2)–H(2)···N(3) hydrogen bonds and π-π stacking interactions in the crystal structure. The preliminary biological test shows that the title compound has a good antitumor activity against A549 in vitro with the IC50 value of 35 μmol/L. 相似文献